1. Latar belakang klinis
Gambaran penyakit
Uraian berikut tersedia dalam bahasa Inggris.
Non-valvular atrial fibrillation (NVAF) is the most common sustained cardiac arrhythmia, characterised by rapid, disorganised atrial electrical activity, loss of effective atrial mechanical contraction, and an irregularly irregular ventricular response. Stasis of blood within the fibrillating left atrium and left atrial appendage promotes thrombus formation; embolisation of these thrombi to the cerebral circulation produces cardioembolic ischaemic stroke, which is typically larger, more disabling and more often fatal than non-cardioembolic stroke. Atrial fibrillation independently increases ischaemic stroke risk roughly four- to five-fold and accounts for a substantial share of strokes in older adults (PMC11850931). NVAF, the indication addressed here, excludes moderate-to-severe mitral stenosis and mechanical prosthetic valves. Because thromboembolic risk is largely modifiable through oral anticoagulation, stroke prevention is the central therapeutic objective in NVAF and the indication modelled here for edoxaban 60 mg once daily (Giugliano 2013; 2024 ESC AF Guidelines).
Epidemiologi
Uraian berikut tersedia dalam bahasa Inggris.
Globally, the Global Burden of Disease Study 2021 estimated 52.55 million prevalent cases of atrial fibrillation/atrial flutter (52,552,045; age-standardised prevalence 620.5 per 100,000), about 4.48 million incident cases, roughly 8.36 million DALYs and 0.34 million deaths annually, with absolute prevalence nearly doubling from 22.2 million in 1990 (an increase of approximately 136%) and continuing to grow (GBD 2021; PMC12133759). Indonesia lacks a nationally representative population prevalence: Riskesdas does not directly measure AF, though it documented rising self-reported stroke prevalence, from 7.0 per 1,000 in 2013 to 10.9 per 1,000 in 2018 (Riskesdas 2018), and stroke is among Indonesia's leading causes of death. The best Indonesian AF estimates are hospital-based: a multicentre tertiary-hospital smartphone-screening study found AF prevalence of approximately 3.2-3.5% (Yuniadi et al., J Arrhythm 2024; PMC11474569), and AF was detected in around 10.8% of ischaemic-stroke admissions (16 of 148; PMC11850931). These figures imply a large, under-detected and under-anticoagulated AF population in Indonesia.
Terapi standar saat ini
Uraian berikut tersedia dalam bahasa Inggris.
The contemporary standard of care for stroke prevention in NVAF is risk-stratified oral anticoagulation guided by the CHA2DS2-VASc (now CHA2DS2-VA) score, with bleeding-risk assessment before initiation. Historically this meant warfarin titrated to an INR of 2.0-3.0; even in the controlled ENGAGE AF-TIMI 48 trial the warfarin arm achieved a median TTR of only 68.4%, illustrating real-world control difficulty (Giugliano 2013). Direct oral anticoagulants (DOACs: apixaban, dabigatran, edoxaban, rivaroxaban) are now preferred over warfarin in eligible patients per the 2024 ESC/EACTS guidelines, except in mechanical valves and moderate-to-severe mitral stenosis where warfarin remains mandatory. In Indonesia, warfarin remains the most accessible and affordable agent and is widely used, but its monitoring burden, interactions and bleeding risk limit effective protection. Indonesian PERKI/InaHRS guidance on NVAF endorses DOACs over warfarin and antiplatelet therapy, though DOAC acquisition cost constrains equitable access under JKN (PERKI/InaHRS NVAF Guideline; 2024 ESC AF Guidelines).
Status regulasi dan penjaminan
Uraian berikut tersedia dalam bahasa Inggris.
Edoxaban (Savaysa/Lixiana, Daiichi Sankyo) received US FDA approval on 8 January 2015 for stroke prevention in NVAF and for VTE, based on ENGAGE AF-TIMI 48, and European Commission marketing authorisation (Lixiana) in 2015 following a positive CHMP opinion. NICE recommended edoxaban for preventing stroke and systemic embolism in adults with NVAF and at least one risk factor in technology appraisal TA355 (23 September 2015). In Indonesia, Lixiana (edoxaban) is registered with BPOM and marketed by PT Kalbe Farma in 15 mg, 30 mg and 60 mg tablets (registration series DKI1808900417, e.g. B1 for the 30 mg and C1 for the 60 mg strength). National reimbursement status warrants verification: the current Formularium Nasional was established by KMK HK.01.07/MENKES/1199/2025; DOAC inclusion and any restriction criteria should be confirmed directly against the live e-Fornas listing (e-fornas.kemkes.go.id) before any reimbursement assumption.
2. Hasil kasus dasar
| Strategi | Biaya terdiskonto | QALY terdiskonto | Tahun hidup |
|---|---|---|---|
| Edoksaban 60 mg sekali sehari | Rp 48,4 juta | 9,659 | 18,41 |
| warfarin dengan target INR 2,0 sampai 3,0 | Rp 41,7 juta | 8,841 | 16,75 |
| Selisih | Rp 6,7 juta | 0,818 | - |
3. Analisis probabilistik
- Simulasi probabilistik (500 sampel)
- Kasus dasar
4. Analisis sensitivitas
- Parameter pada nilai rendah
- Parameter pada nilai tinggi
5. Analisis skenario
| Skenario | Selisih QALY | Selisih biaya | Rasio per QALY |
|---|---|---|---|
| Base case (30 yr) | 0,818 | Rp 6,7 juta | Rp 8,2 juta |
| 5-year horizon | 0,053 | Rp 6,9 juta | Rp 129,2 juta |
| 10-year horizon | 0,197 | Rp 5,5 juta | Rp 27,8 juta |
| 20-year horizon | 0,544 | Rp 5,2 juta | Rp 9,6 juta |
| 0% discount rate | 1,372 | Rp 8,1 juta | Rp 5,9 juta |
| 5% discount rate | 0,600 | Rp 6,3 juta | Rp 10,4 juta |
| Poor real-world INR control (warfarin stroke x1.3) | 0,826 | Rp 6,8 juta | Rp 8,3 juta |
| Edoxaban at full retail price (~Rp14.6M/yr) | 0,818 | Rp 10,2 juta | Rp 12,4 juta |
6. Validasi model
Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).
| Luaran pembanding | Prediksi model | Data terbit | Sumber |
|---|---|---|---|
| Stroke / systemic embolism annual incidence (warfarin arm) | 1,1% | 1,5% | ENGAGE AF-TIMI 48 warfarin arm: stroke or systemic embolism 1.50%/yr (modified ITT primary efficacy). Giugliano RP et al |
| Major bleeding annual incidence (warfarin arm) | 2,6% | 3,4% | ENGAGE AF-TIMI 48 warfarin arm: major bleeding 3.43%/yr (ISTH definition, includes intracranial). Giugliano RP et al. N |
| Intracranial haemorrhage annual incidence (warfarin arm) | 0,8% | 0,8% | ENGAGE AF-TIMI 48 warfarin arm: intracranial haemorrhage 0.85%/yr vs edoxaban 60 mg 0.39%/yr (HR 0.47). Giugliano RP et |
| All-cause mortality at 10 yr (NVAF age 70+, warfarin arm) | 32,3% | 38,0% | ENGAGE AF-TIMI 48 warfarin all-cause mortality 4.35%/yr; compounded over a 10-yr elderly NVAF horizon (~1 - 0.9565^10 = |
7. Penyesuaian untuk Indonesia
Uraian berikut tersedia dalam bahasa Inggris.
- NICE TA355 (2015) recommends edoxaban as an option for preventing stroke and systemic embolism in NVAF with 1+ risk factor, judged cost-effective vs warfarin (committee ICER GBP 16,000-22,100/QALY).
- Indonesia base case compares edoxaban with warfarin because warfarin is the pragmatic BPJS baseline and DOAC access is cost-constrained under JKN.
- Lower real-world INR control across many kabupaten (TTR well below ENGAGE 68.4%) would raise warfarin event rates and improve edoxaban's relative value; tested in the poor-INR-control scenario.
- Budget impact may dominate affordability: NVAF prevalence rises steeply with age and anticoagulation is lifelong; eligible population is large and under-treated.
- Confirm Fornas/e-Fornas listing and any restriction criteria (KMK HK.01.07/MENKES/1199/2025) and BPOM registration (Lixiana 15/30/60 mg, PT Kalbe Farma) before reimbursement interpretation.
- Threshold uses 1x and 3x GDP proxy only; InaHTAC may apply different decision rules.